Human antibodies to GREM1
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsAris N. Economides, Vincent J. Idone, Lori C. Morton
Life of this patent
Estimating the term…
Abstract
The present invention provides antibodies that bind to human gremlin-1 (GREM1), and methods of use. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to GREM1. The antibodies of the invention are useful for inhibiting or neutralizing GREM1 activity, thus providing a means of treating a GREM1-related disease or disorder such as fibrosis and cancer. In some embodiments, the antibodies of the present invention are used in treating at least one symptom or complication of fibrosis of the liver, lungs or kidney.
Claims13
An isolated human monoclonal antibody or antigen-binding fragment thereof that binds specifically to human gremlin-1 (GREM1), and blocks GREM1-mediated inhibition of bone morphogenetic protein (BMP) signaling, wherein the antibody or antigen-binding fragment comprises the six complementarity determining regions (HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3) contained within the HCVR/LCVR amino acid sequence pair of SEQ ID NOs:
- 434/442.
Dependencies are inferred from the claim text.